GlassScriptPhysician profile
David W Koeper
NPI 1487698387
$5,283.04
in general payments reported to CMS, 2019-2025
35 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $572 · 2021: $750 · 2022: $806 · 2023: $960 · 2024: $796 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435 · Consulting Fee: $140 · Education: $41.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.70 |
| Consulting Fee | $140.00 |
| Education | $41.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $679.22 | 2019-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $634.00 | 2019-2025 | Benlysta, Jesduvroq |
| Astrazeneca Pharmaceuticals LP | $526.15 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $448.68 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $285.31 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $278.84 | 2019-2023 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $235.62 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $193.42 | 2019-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $170.22 | 2021-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $155.09 | 2020-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $150.78 | 2024-2025 | |
| Travere Therapeutics, INC. | $139.65 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $123.55 | 2020-2024 | Crysvita |
| Aurinia Pharma U.S., INC. | $120.30 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $117.26 | 2024-2025 | Ibsrela |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Koeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.